摘要
众所周知,心血管疾病是2型糖尿病患者发病和死亡的主要原因。在过去的几年里,讨论最多的话题之一是抗糖尿病药物的CV安全性。关于老年抗糖尿病药物的CV安全性,数据不太清楚,关于其CV安全性的结论主要是基于旨在评估其降糖效果的随机对照试验。在这篇综述中,我们总结了当前有关旧的和新的抗糖尿病药物的CV安全性的知识。根据已发表的文献,二甲双胍是治疗2型糖尿病的第一种药物,似乎具有心脏保护作用。当二甲双胍单药不能达到HbA1c靶点时,第二线药物的选择就不那么清楚了。根据EMPA-Reg结果试验的发现和最近发表的6项试验的领导者和持续6项试验,表观利氟嗪、利拉格鲁帝和半谷胱甘肽作为CV病患者的二线药物似乎是合理的选择。另一方面,磺脲类药物,除格列齐特外,应在这些患者中加以避免,尽管目前尚缺乏CV安全性试验。在没有CV疾病的个体中,任何其他类型的抗糖尿病药物都可以通过以病人为中心的方法来选择。Saxagliptin、alogliptin、sitagliptin和Lixisenatide已在CV安全性试验中得到评价,并对CV结果产生中性影响,而吡格列酮可能具有一定的CV效果。然而,在心力衰竭患者中应避免使用沙司他汀和阿霉素,而吡格列酮在这一人群中是违禁的。
关键词: 心血管事件,二甲双胍,磺脲,吡格列酮,胰岛素,二肽酰肽酶-4抑制剂,胰高血糖素样肽-1受体激动剂,钠-葡萄糖共转运蛋白-2抑制剂。
Current Medicinal Chemistry
Title:Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Volume: 25 Issue: 13
关键词: 心血管事件,二甲双胍,磺脲,吡格列酮,胰岛素,二肽酰肽酶-4抑制剂,胰高血糖素样肽-1受体激动剂,钠-葡萄糖共转运蛋白-2抑制剂。
摘要: It is known that Cardiovascular (CV) disease is the leading cause of morbidity and mortality in individuals with type 2 diabetes. Over the last years, one of the most discussed topics is the CV safety of anti-diabetic medications. Regarding CV safety of older antidiabetic agents the data are less clear and conclusions about their CV safety are mostly based on randomized controlled trials designed to assess their glucose lowering efficacy. In this review, we summarize the current knowledge about the CV safety of older and newer antidiabetic medications.
According to the published literature metformin is the first line agent for the treatment of type 2 diabetes and seems to have cardio-protective effects. The choice of the second line agent when metformin monotherapy fails to achieve HbA1c targets is less clear. In the light of the findings of the EMPA-REG OUTCOME trial and the recently published LEADER and SUSTAIN 6 trials, empagliflozin, liraglutide and semaglutide seem reasonable options as second line agents for patients with CV disease. Sulfonylureas on the other hand, with the exception of gliclazide, should be avoided in those patients, although CV safety trials are still lacking. In individuals without CV disease any of the other classes of anti-diabetic medication can be selected on a patient-centered approach. Saxagliptin, alogliptin, sitagliptin and lixisenatide have been evaluated in CV safety trials and have neutral effects on CV outcomes, while pioglitazone may have some CV benefits. Saxagliptin and alogliptin, however, should be avoided in patients with heart failure, while pioglitazone is contraindicated in this population.
Export Options
About this article
Cite this article as:
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications, Current Medicinal Chemistry 2018; 25 (13) . https://dx.doi.org/10.2174/0929867324666170530075533
DOI https://dx.doi.org/10.2174/0929867324666170530075533 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design CD44 and its Role in Inflammation and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment
Current Pharmaceutical Design Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued) Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Imaging of Abdominal Aortic Aneurysm: The Present and the Future
Current Vascular Pharmacology Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures
Current Drug Targets The Pathway Less Traveled: Moving from Candidate Genes to Candidate Pathways in the Analysis of Genome-Wide Data from Large Scale Pharmacogenetic Association Studies
Current Pharmacogenomics and Personalized Medicine Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets